Stock-Based Compensation | 5. Stock-Based Compensation The compensation costs that have been charged against income for the thirteen weeks ended April 29, 2017 and April 30, 2016 were as follows (in thousands): Thirteen Weeks Ended April 29, 2017 April 30, 2016 Stock-based compensation expense by type: Stock options $ 173 $ 381 Restricted stock unit awards, including performance-based 1,491 1,709 Employee stock purchases 33 36 Director deferred compensation 6 23 Total stock-based compensation expense 1,703 2,149 Income tax benefit recognized 614 781 Stock-based compensation expense, net of income tax $ 1,089 $ 1,368 In the thirteen weeks ended April 29, 2017 and April 30, 2016, we granted the following equity awards: Thirteen Weeks Ended April 29, 2017 April 30, 2016 Stock options 20,372 36,041 Restricted stock unit awards 108,429 100,775 Performance-based restricted stock unit awards 54,900 45,300 Deferred stock units 201 13,482 At April 29, 2017, the total compensation costs, related to nonvested restricted stock unit awards not yet recognized was $9.4 million and the weighted-average period over which such awards are expected to be recognized was 2.8 years. There are no future compensation costs related to nonvested stock options to be recognized at April 29, 2017. Under the 2012 Non-Employee Director Equity Plan (2012 Plan), a total of 3,361 and 2,851 shares of our common stock were awarded during the thirteen weeks ended April 29, 2017 and April 30, 2016, respectively, as part of the annual equity award to directors in the first quarter. The weighted-average grant date fair value of stock options granted during the thirteen weeks ended April 29, 2017 and April 30, 2016 was $8.47 and $10.56 per share, respectively. Our employee purchases of common stock, the average price per share and the weighted-average grant date fair value of shares purchased through the our employee stock purchase plan were as follow: Thirteen Weeks Ended April 29, 2017 April 30, 2016 Shares purchased 5,464 5,617 Average price per share $ 25.08 $ 25.70 Weighted average fair value at grant date $ 5.59 $ 6.47 |